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Purpose: Respiratory infection is the most common cause for acute exacerbation of chronic 
obstructive pulmonary disease (AE-COPD). The aim of this work was to study the etiology of 
the respiratory infection in order to assess the usefulness of the clinical and analytical parameters 
used for COPD identification.
Patients and methods: We included 132 patients over a period of 2 years. The etiology of 
the respiratory infection was studied by conventional sputum, paired serology tests for atypical 
bacteria, and viral diagnostic techniques (immunochromatography, immunofluorescence, cell 
culture, and molecular biology techniques). We grouped the patients into four groups based on 
the pathogens isolated (bacterial versus. viral, known etiology versus unknown etiology) and 
compared the groups.
Results: A pathogen was identified in 48 patients. The pathogen was identified through   sputum 
culture in 34 patients, seroconversion in three patients, and a positive result from viral   techniques 
in 14 patients. No significant differences in identifying etiology were observed in the clinical 
and analytical parameters within the different groups. The most cost-effective tests were the 
sputum test and the polymerase chain reaction.
Conclusion: Based on our experience, clinical and analytical parameters are not useful for the 
etiological identification of COPD exacerbations. Diagnosing COPD exacerbation is difficult, 
with the conventional sputum test for bacterial etiology and molecular biology techniques for 
viral etiology providing the most profitability. Further studies are necessary to identify respiratory 
syndromes or analytical parameters that can be used to identify the etiology of new AE-COPD 
cases without the laborious diagnostic techniques.
Keywords: respiratory viruses, chronic obstructive pulmonary disease, exacerbation, diagnostic 
tests, hospitalization
Introduction
Chronic obstructive pulmonary disease (COPD) is associated with significant morbidity 
and mortality, with the World Health Organization estimating its rise from being the 
fifth to the third leading cause of death by 2030.1 The overall prevalence of COPD in 
Spain is estimated to be 10.2%.2
COPD is a slow, progressive disease, with patients experiencing episodes of acute 
deterioration known as exacerbations,3 which increase in frequency and severity with 
disease progression.
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The causes of acute exacerbations of COPD (AE-COPD) 
are multifactorial. Half of the AE-COPD cases are attributed 
to respiratory infections (50%), but exacerbations are also 
associated with pollution, temperature changes, allergens 
(30%), and other comorbidities (26%) such as heart failure 
and pulmonary thromboembolism.4
In several studies, the presence of bacteria in AE-COPD 
has been associated with purulence of the sputum and 
the presence of inflammatory markers.5,6 In recent years, 
  emerging new diagnostic techniques have revealed a relation-
ship with respiratory viruses.7–10 In addition, the etiology of 
respiratory infections in AE-COPD patients differs according 
to the geographic area.11
Currently, AE-COPD patients are treated with antibiotics 
as the first line of defense, depending on the severity of the 
COPD and the severity of the exacerbation itself.12 With the 
emergence of multidrug resistance and increased economic 
spending on antibiotic therapy, numerous studies have assessed 
the benefit of antibiotic treatment,13,14 recommending a short 
course of antibiotic treatment for slight exacerbations.15
Similarly, biological markers such as procalcitonin have 
been proposed as markers for antibiotic administration 
in the AE-COPD,16 allowing a reduction in antibiotic 
prescriptions.
The identification of respiratory viruses as a cause for AE-
COPD may help reduce the use of antibiotics. Therefore, it is 
important to find clinical and analytical parameters that could 
guide us in identifying the etiology of new AE-COPD cases, 
especially considering the laborious diagnostic techniques 
currently used for diagnosis.
The aims of our study were to identify the etiology of 
respiratory infections in patients hospitalized for AE-COPD 
using different diagnostic tests and to evaluate the usefulness 
of the clinical and analytical parameters of the diagnostic 
process.
Materials and methods
We included patients who were consecutively admitted to 
the Hospital of Mataró with AE-COPD between April 1, 
2005 and March 31, 2007. COPD was defined according to 
the global initiative for chronic obstructive pulmonary dis-
ease (GOLD) criteria,17 with patients exhibiting compatible 
spirometry measurements and a smoking history of at least 
ten packs/year. A diagnosis of acute exacerbation (AE) was 
assumed when a minimum of two Anthonisen criteria18 were 
present. Any patient with COPD decompensation that was 
caused by a noninfectious disease was excluded from the 
study, assuming that the selected patients presented with an 
upper or lower respiratory tract infection.
Identification was made based on the respiratory infection 
and dyspnea admission diagnoses from the International 
Statistical Classification of Diseases, Ninth Revision, Clinical 
Modification (ICD-9-CM)19,20 (491, 492, 493, 496, 518.81, 
464, 465, 466, 519.11, 786.0), excluding the patients who 
had a known cause of respiratory failure that was differ-
ent from infectious exacerbation (heart failure, pulmonary 
  thromboembolism, pneumonia). Finally, the patients who 
met the inclusion criteria and none of the exclusion criteria 
(severe   immunosuppression, the need for mechanical ventila-
tion or   admittance to the Intensive Care Unit, arrival from a 
nursing home, or a terminal stage of the disease) were asked 
for their informed consent.
The study was approved by the Consorci Sanitari del 
Maresme Ethics Committee of the Hospital of Mataró.
Demographic data
Upon admission, a complete clinical history and physical 
exam were performed. Each patient’s demographic and 
l  ifestyle characteristics, baseline dyspnea (based on the 
  Dyspnea Scale from the Medical Research Council21), 
  exacerbation history, history of pneumonia, and hospital 
admissions during the previous year were evaluated.
The contact with family members at home suffering from 
an upper respiratory tract infection was collected.
Clinical data
We obtained information on each patient’s upper   respiratory 
tract (nasal congestion, rhinorrhea, and sneezing), lower 
respiratory tract (cough and expectoration), and constitutional 
symptoms (dysthermia, fever, chills, asthenia, anorexia, 
headache, arthromyalgia, and impaired consciousness).
Upon admission, the severity of the exacerbation was 
classified (depending on the presence of respiratory failure, 
severe cyanosis, baseline dyspnea deterioration, the utilization 
of accessory muscles, the worsening of blood gas levels, and 
a blood pH , 7.35), as were the severity of COPD (according 
to the GOLD criteria)17 and COPD prognosis (according to 
the body mass, airflow obstruction, dyspnea, and exercise 
capacity [BODE] multidimensional index).22
Vital signs and anthropometric data were collected 
from each patient, and a chest radiograph was taken to rule 
out pneumonia. Baseline spirometry measurements were 
collected, and each patient’s treatment before and during 
hospitalization for AE-COPD was recorded.
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Analytical data
A baseline blood gas reading, a complete cell blood count 
(CBC), and basic biochemistry readings (AST, ALT, 
  creatinine, urea, glucose, and electrolytes) were collected 
from each patient upon arrival to the emergency room. 
A routine blood analysis that included total protein and a 
protein profile was performed the following day.
Microbiological study
Conventional sputum
Upon hospital admission, the sputum was collected upon 
spontaneous expectoration in a conventional manner with or 
without using mucolytic agents. Sputa were collected before 
starting antibiotic treatment at the hospital. The sputa were 
cultured only if the quality criteria were met in a sputum 
Gram stain (,10 epithelial cells and .25 polymorphonuclear 
leukocytes).23
Paired serologies
Sera were collected from patients at admission and 4 weeks 
after the initial collection for a second paired   serology. 
Passive agglutination techniques were used to detect 
  Mycoplasma pneumoniae, and microimmunofluorescence 
was used to detect Chlamydia species.
Nasopharyngeal lavage (NPL)
The NPL and the nasal exudate that were collected 24 hours 
after admission were used for viral detection. The different 
techniques that were performed are detailed below.
Immunochromatography was used to rapidly detect 
antigens from influenza viruses A and B or respiratory 
  syncytial virus (RSV). The BinaxNOW Influenza A and B® 
and BinaxNOW RSV® tests (Binax Inc, Scarborough, ME) 
were used according to the manufacturer’s instructions.
Immunofluorescence techniques were used to detect 
influenza viruses A and B, adenovirus, parainfluenza virus, 
and RSV .
The replication of influenza viruses A and B, adenovirus, 
parainfluenza, rhinovirus, and RSV was detected in cell 
culture.
We determined the presence of nucleic acids from 
influenza viruses A and B, RSV A and B, parainfluenza 1, 
2, 3, and 4, coronaviruses 229E and OC43, rhinovirus, and 
metapneumovirus. The RealAccurate™ Respiratory RT-PCR 
Kit (PathoFinder, Maastricht, Netherlands) was used for the 
nucleic acid and respiratory virus amplification test, and the 
QIAamp Viral RNA Mini Kit (QIAGEN Iberia SL, Madrid, 
Spain) was used to extract RNA from clinical samples. The 
RealAccurate™ Respiratory RT-PCR kit (PathoFinder) 
  consists of ready-to-use solutions that contain primers 
and TaqMan probes that were used in accordance with the 
conditions set by the manufacturer.
Follow-up
In a control visit performed one week after admission or 
coinciding with hospital discharge, we recorded the evolution 
of the episode with regards to clinical symptoms, physical 
examination, and treatment. In conjunction with the earlier 
episode evaluation, we identified cases of treatment failure 
(identified as the persistence of hemodynamic alterations, 
respiratory failure, severe adverse effects, or a lack of 
treatment response).
The length of hospital stay and possible complications 
were also included.
Statistical analysis
The data were collected in a Microsoft Access database 
and analyzed using SPSS for Windows, version 14.0 (IBM 
Corporation, Armonk, NY).
The qualitative variables are expressed as counts and 
percentages, while the quantitative variables are expressed 
as means and standard deviations or interquartile range. 
Comparisons between means were performed using the 
Student’s t-test for independent samples or the Mann–
Whitney U test for variables that did not meet the criteria of 
normality. For comparisons of proportions, the Chi-square 
or Fisher’s exact test was used. In all cases, we considered 
values of P , 0.05 to indicate significant differences.
To study the relationship between the analytical and 
  clinical parameters and the etiology of AE-COPD, three 
groups were categorized. Group 1 contained patients 
for whom a virus was detected with diagnostic tests, 
group 2 included the patients who exhibited the detection of 
  bacteria only, and group 3 contained patients with unknown 
etiologies.
Results
During the study period, 718 consecutive patients were admit-
ted to the hospital with a diagnosis of respiratory infection 
and dyspnea according to ICD-9-CM guidelines.18
We included 155 patients based on the inclusion and 
exclusion criteria. In six patients with the clinical criteria 
for chronic bronchitis, spirometry was not performed in the 
follow-up. Finally, 17 of the 148 remaining patients were 
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excluded because the follow-up spirometry readings were 
not compatible with an infection.
Thus, we studied 132 patients with AE-COPD of 
a probable infectious origin who met the inclusion 
  criteria and had no other causes of acute decompensation 
(Figure 1).
The demographics of the patients and the baseline char-
acteristics of AE-COPD are presented in Tables 1 and 3.
The patients were hospitalized in the following depart-
ments: Internal Medicine (48.5%), Pneumology (33.3%), 
and the Short Stay Unit (18.2%).
Over the course of two years, the admissions peaks 
  coincided with seasonal variations, exhibiting two annual 
peaks (spring and winter) (Figure 2).
A total of 51 pathogens were isolated. Of these, 37 were 
bacterial and 14 were viral.
Of the 73 sputum samples surveyed, 19 were Gram-
positive, 17 were Gram-negative, and 37 contained 
polymorphonuclear cells without bacteria. In addition, 
Ziehl–Neelsen staining was performed in 26 samples, all of 
which had a   negative result. The culture results were   positive 
in 34 patients (Table 2), with higher numbers of patients 
exhibiting H. influenzae and P . aeruginosa.
We obtained two positive serologies for Mycoplasma 
pneumoniae (1.5%) and one for Chlamydia pneumo-
niae (0.8%).
An NPL was collected from all patients to detect a 
  possible viral etiology. We identified a positive result in 
14 patients and found herpes virus type-1 in two patients. 
The detection of herpes virus type-1 was attributed to 
  contamination. So then, we identified a positive result from 
viral techniques in 12 patients.
An etiological agent was identified in 48 of the patients 
(36.3%), and an unknown AE-COPD etiology was assigned 
to 84 patients (63.7%).
A bacterial agent was identified as the etiological agent 
in 33 patients (24.1%), with mixed bacterial etiology in two 
patients (S. pneumoniae plus S. marcescens and H. influenzae 
and C. pneumoniae). We identified a positive result to Myco-
bacterium spp. by sputum.
A virus was isolated in 12 patients (9%); and two patients 
exhibited exacerbations attributable to a mixed etiology 
718
352 209 155 132 AE-COPD
6 No spirometry
17 FVC/FEV1 >70
48 Pulmonary comorbidity
121  Asthma
  92  Heart failure
148  Bronchopathy
    5  Pneumonia
32 No consent
22 Sociopathy and
     others 
Hospitalized
patients
16 Extrapulmonary comorbidity
2 Immunodeficiency
4 Intensive care unit
14 Terminal COPD
34 Health care institutions
25 Hospitalization last 30 days 
Figure 1 Recruitment flowchart and the identification of eligible patients.
Abbreviations: AE-COPD, acute exacetbation of chronic obstructive pulmonary disease; FVC/FEV1, forced vital capacity to forced expiratory volume in 1 second ratio.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
330
Boixeda et alInternational Journal of COPD 2012:7
(1.5%), E. coli plus influenza A virus and P . aeruginosa plus 
coronavirus.
The efficiencies of the diagnostic tests are shown in 
Table 2.
We compared the characteristics of the patients using 
  bacterial and viral isolation. When we assessed the   clinical and 
analytical parameters of AE-COPD according to etiological 
diagnoses, no significant differences were observed, with the 
exception of the lymphocyte count for the patients whose 
AE-COPD was attributed to a virus (Table 3).
We obtained statistically significant differences between 
the analytical datasets for the patients with known and 
unknown etiologies. In patients with an unknown etiology, 
we observed a greater decrease in the pH and pO2 in the 
baseline arterial blood gas upon arrival at the emergency 
room, as well as a greater leukocytosis and increased heart 
rate (Table 3).
Evaluation of AE-COPD
The evaluation of AE-COPD after a week of hospital 
admission revealed clinical improvement in the majority of 
patients (92.3%). Treatment failure was observed in seven 
patients (5.4%), and no positive changes were observed in 
three patients (2.3%). Treatment failure was evidenced by 
the worsening of respiratory failure in three patients, severe 
adverse effects in two patients, and a lack of treatment 
response in four patients.
Only one patient died during hospitalization.
Discussion
This prospective observational study of patients admitted 
for AE-COPD (VIR-AE) included a 2-year follow-up period 
and was intended to identify the infectious etiology of  COPD 
  exacerbations (whether viral or bacterial), as well as to 
describe the clinical features and analytical variables 
used to differentiate the cause of exacerbation.
An infectious cause was identified in 48 of the 132 patients 
included in this study (36.3%). A bacterial etiology was 
identified in 33 patients, a viral infection was observed in 
12 patients, and two patients had mixed etiology. A higher 
sensitivity was observed with the conventional sputum analy-
sis and the polymerase chain reaction technique (PCR) for 
the NPL analysis.
The clinical and laboratory variables that were evaluated 
for the diagnosis were practically the same for the bacterial 
and viral etiology cases, with the exception of a   relative 
lymphocyte count that was lower in the group with viral 
etiology and a longer hospitalization period in patients with 
bacterial infections. We attributed the longer hospital stay to 
parenteral treatment after finding multiresistant   bacteria in 
some patients with bacterial etiology.
Other studies have identified clinical symptoms such 
colds or a sore throat upon the isolation of rhinovirus,8 or even 
when rhinorrhea was associated with a bacterial etiology.24 
Table 1 Patient characteristics
Category/parameter Total (n = 132)
Sociodemographics
Age, mean (SD), years 72.9 (8.6)
Male 129 (97.7)
Body mass index, mean (SD) 26.8 (4.5)
Smokers 31 (23.5)
Occupational risk 48 (36.4)
Influenza vaccination 91 (68.9)
Streptococcus pneumoniae vaccination 28 (21.2)
Acute COPD exacerbation in last year 89 (67.4)
Hospitalization in last year 47 (35.6)
Pneumonia in last year 8 (6.1)
Treatment
Chronic oxygen therapy 23 (17.4)
Chronic antibiotherapy 15 (11.4)
Antibiotics previous hospitalization 46 (34.8)
Corticosteroids previous hospitalization 44 (33.3)
Comorbidities
Hypertension 62 (47)
Diabetes mellitus 42 (31.8)
Auricular fibrillation 26 (19.7)
Ischemic heart disease 19 (14.4)
Neoplasm 18 (13.6)
Sleep apnea-hypopnea syndrome 14 (10.6)
Severity
Pre-bronchodilator spirometry, mean (SD)
  FEV1, mL 1138 (434)
  FVC, ml 2415 (720)
  FEV1, % 41.3 (15)
  FVC, % 61.2 (16.6)
Post-bronchodilator spirometry, mean (SD)
  FEV1, mL 1203 (453)
  FVC, ml 2565 (733)
  FEV1/FVC, % 46.9 (11.2)
COPD severity as per GOLD
  Mild (.80) 3 (2.3)
  Moderate (50–80) 38 (29)
  Severe (30–50) 68 (51.9)
  Very severe (,30) 22 (16.8)
Baseline BODE score
  0–2 43 (32.6)
  3–4 44 (33.3)
  5–6 26 (19.7)
  7–10 7 (5.3)
Notes: Data are expressed as number (%) unless otherwise indicated. Influenza 
vaccination  within  the  current  influenza  season;  pneumococcal  polysaccharide 
vaccination within the previous 5 years.
Abbreviations:  BODE,  body  mass,  airflow  obstruction,  dyspnea,  and  exercise 
capacity  multidimensional  index;  COPD,  chronic  obstructive  pulmonary  disease; 
FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; gOlD, global 
initiative for chronic obstructive pulmonary disease.
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However, we have not identified any clinical symptom as 
indicative of a viral etiology in this study, probably because 
of the sample size.
We have also identified a greater involvement of baseline 
arterial blood gas (a decrease in pH and PO2) in the group 
with an unknown etiology, as well as increased leukocytosis 
and heart rate, which could mean that a bronchospasm 
component contributes to the AE-COPD within this group.
In addition to bronchospasm, other causes of AE-COPD 
such as heart failure or pulmonary thromboembolism were 
likely to be excluded from our study due to the fact that we 
only selected a population with a highly suspicious respira-
tory infection. Similarly, we excluded patients coming from 
residential centers, patients admitted to the hospital in the 
30 days prior to their current admission, and patients trans-
ferred from the intensive care unit in order to eliminate any 
hospital-acquired infections. This comprehensive selection 
of patients may limit the external validity of our results.
We observed a mean age of 73 years (range 51–88 years) 
and a smoking history in all of our patients (23.5% were 
active smokers), which is probably due to the high percentage 
of men in our study.
The diagnosis of COPD exacerbation is a matter of 
debate. The most frequent cause of COPD exacerbation is 
considered to be viral or bacterial bronchial infection.25 This 
fact is based on the regular presence of purulent coughing 
and bacterial isolation from the cough of more than half of 
the patients with exacerbations.26 In addition, up to 30% of 
patients with stable COPD had evidence of bronchial bacte-
rial colonization in the absence of AE-EPOC.6 However, 
authors such as Sethi et al have demonstrated that pathogen 
colonization is not responsible for the exacerbation, as for 
Haemophilus, where infection with an additional bacterial 
strain is necessary to elicit an exacerbation.27
The identification of a bacterial etiology for AE-COPD is 
primarily obtained through the study of sputum. We obtained 
sputum in 65% of patients, which shows the difficulty of 
obtaining it in clinical practice. A mixed respiratory flora 
was obtained in 37% of these patients and was diagnostic 
in 24.2%, with the samples exhibiting a predominance of 
H. influenzae and P . aeruginosa. It is important to note 
that our patients had severe COPD exacerbations that 
caused respiratory failure and required hospital admission. 
H.   influenzae and P . aeruginosa were detected mainly in 
the patients with severe COPD, which could explain the 
inability to isolate bacteria such as Pneumococcus and 
viruses, as severe COPD benefits the enterobacteria and 
P . aeruginosa.
The routine use of serology is not useful for the diagnosis 
of acute Mycoplasma pneumoniae or Chlamydia infection.
From the point of view of viral etiology, PCR   techniques 
have been performed on the bronchial exudate of COPD 
Table 2 Diagnostic test results and yields
Etiology Detection method
Sputum Serology RIT DFA Viral culture NAT Total detected
Bacterial
  Streptococcus pneumoniae 2 – – – – – 2
  Haemophilus influenza 11 – – – – – 11
  Moraxella catarrhalis 3 – – – – – 3
  Pseudomonas aeruginosa 13 – – – – – 13
  Escherichia coli 3 – – – – – 3
  Streptococcus marcescens 1 – – – – – 1
  Mycobacterium spp. 1 – – – – – 1
  Chlamydophila pneumoniae – 1 – – – – 1
  Mycoplasma pneumoniae – 2 – – – – 2
Viral
  Respiratory syncytial virus – – – 3 0 2 4
  Rhinovirus – – – – 1 1 2
  Parainfluenza virus – – – 1 1 1 2
  Human metapneumovirus – – – – – 2 2
  Coronavirus – – – – – 2 2
  Adenovirus – – – – 1 – 1
  Influenza A virus – – – 1 – – 1
Total (positive test/total test) 34/73 3/131 0/130 5/130 3/128 8/30 51
Notes: Mixed cases included the following pathogens: Chlamydophila pneumoniae plus Haemophilus influenzae, Escherichia coli plus influenza A virus, Pseudomonas aeruginosa 
plus coronavirus, Streptococcus pneumoniae plus Streptococcus marcescens.
Abbreviations: DFA, direct fluorescent test; NAT, nucleic acid amplification test; RIT, rapid immunochromatographic test.
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patients, with a virus being detected in 23% of the 
exacerbations.28 In our study, the result was lower, as we 
detected a virus in 10% of all the AE-COPD cases, with 
little evidence of influenza virus in our sample. This could 
be explained due to the fact that an influenza epidemic was 
not identified during the study period.29
The discrepancies between our data and the data 
from other studies could also be explained by the differ-
ent samples and techniques used. For example, higher 
percentage were obtained of sputum samples than NPL 
samples (47% and 31%, respectively).9 In reference to the 
literature, we probably could have obtained better results by 
analyzing the sputum rather than obtaining the NPL for 
virological diagnostic techniques.
Even so, based on the results obtained, we can state that viral 
infections could be the cause of AE-COPD. We should have 
this in mind at the time of prescribing antibiotics, especially 
in a slightly sick patient who presents no purulent sputum.
Viral disease has a seasonal distribution, and therefore, 
efforts to confirm the diagnosis in routine clinical practice 
Table 3 Characteristics and severity of AE-COPD
Category/parameter Total  
(n = 132)
Bacterial  
etiology  
(n = 33)
Viral  
etiology  
(n = 12)
Unknown 
etiology  
(n = 84)
P value  
(viral versus 
bacterial 
infection)
P value  
(known versus 
unknown 
infection)*
Signs and symptoms
Acute onset 61 (46.2) 17 (51.5) 8(61.5) 36 (43.4) 0.54 0.23
Cough 114 (86.4) 29 (87.9) 13(100) 70 (84.3) 0.19 0.26
Expectoration 102 (77.3) 25 (75.8) 12 (92.3) 63 (75.9) 0.41 0.57
Purulent sputum 59 (57.8) 15 (60) 7 (58.3) 35 (57.3) 0.59 0.70
Fever 45 (34.1) 9 (27.3) 5 (38.5) 30 (36.1) 0.50 0.80
Chills 55 (41.7) 11 (33.3) 7 (53.8) 37 (44.6) 0.19 0.54
Nasal congestion 69 (52.3) 12 (36.4) 7 (53.8) 48 (57.8) 0.27 0.07
Rhinorrhea 63 (47.7) 11 (33.3) 7 (53.8) 43 (51.8) 0.19 0.16
Sore throat 29 (22) 7 (21.2) 6 (46.2) 15 (18.1) 0.14 0.17
Headache 35 (26.5) 10 (30.3) 2 (15.4) 22 (26.8) 0.46 0.92
Arthromyalgia 46 (34.8) 8 (24.2) 4 (30.8) 32 (39) 0.71 0.13
Sneezing 67 (50.8) 13 (39.4) 8 (61.5) 45 (54.2) 0.17 0.35
Tearing eyes 30 (22.7) 7 (21.2) 3 (23.1) 20 (24.1) 0.89 0.76
Hoarseness 87 (65.9) 22 (66.7) 9 (69.2) 55 (66.3) 0.86 0.89
Asthenia 104 (78.8) 28 (84.8) 11 (84.6) 63 (76.8) 0.98 0.28
Anorexia 60 (45.5) 16 (48.5) 8 (61.5) 34 (41.5) 0.42 0.24
Contact with illness 40 (30.3) 10 (30.3) 4 (30.8) 25 (30.9) 0.97 0.96
Contact with children 28 (21.2) 4 (12.1) 5 (38.5) 19 (23.2) 0.92 0.63
Contact with ill child 17 (12.9) 3 (9.1) 3 (23.1) 11 (13.4) 0.33 0.95
Cardiac pulse, mean (SD) 97.1 (18) 88.9 (16) 96.7 (14) 99.8 (18) 0.1 0.015
Respiration rate, mean (sD) 28.4 (7.3) 27.9 (8.3) 27.2 (6.1) 28.7 (7) 0.98 0.37
Analytical tests, mean (SD)
pH 7.42 (0.06) 7.44 (0.05) 7.44 (0.04) 7.4 (0.6) 0.98 0.002
PaCO2, mmHg 44.1 (9.2) 43.1 (8) 40.5 (5.9) 45 (9.9) 0.53 0.16
PO2, mmHg 57.4 (14.3) 58 (9.8) 63 (8.2) 56.7 (16) 0.10 0.048
SatO2, % 88.2 (7) 89.7 (4.8) 92.2 (2.9) 87.2 (7.6) 0.08 0.006
Leukocytes, ×103/mm 12994 (5) 11991 (5) 10590 (3) 13293 (5) 0.29 0.04
Lymphocytes, % 11.3 (7) 13.8 (8.8) 9.3 (7) 10.7 (5.9) 0.034 0.40
Alanine transferase, U/L 22.4 (12.5) 24.1 (10) 23.9 (11.4) 21.7 (13) 0.64 0.03
Creatinine, mg/dL 1.03 (0.9) 0.84 (0.2) 0.93 (0.3) 1.11 (1) 0.24 0.03
Gamma globulin, % 12.8 (4) 13.8 (4.8) 11.4 (2.4) 12.6 (3.8) 0.05 0.25
AE-COPD severity
Post-BD FEV1, % predicted 44.1 (15) 39.4 (13.6) 44.3 (15) 46.4 (15) 0.15 0.045
Hospitalization last 6 months 45 (34.1) 13 (39.4) 4 (30.8) 28 (33.3) 0.74 0.67
Disease duration, mean (SD), d 7.8 (7.5) 8 (7.6) 8.15 (8.7) 7.7 (7.4) 0.91 0.88
Hospital stay, mean (SD), d 9.2 (6.8) 11.7 (7.8) 7.5 (4) 8.4 (6.4) 0.05 0.015
Notes: Data are expressed as number (%) unless otherwise indicated. *We compared the patients with known diagnostic (33 as bacterial, 12 as viral, 2 as mixed viral and 
bacterial, and 1 as Mycobacterium spp.) and unknown diagnostic.
Abbreviations: AE-COPD, acute chronic obstructive pulmonary disease exacerbation; CRP, C-reactive protein; NAT, nucleic acid amplification test; PaCO2, partial pressure 
of carbon dioxide; PO2, partial pressure of oxygen; Post-BD FEV1, post-bronchodilator forced expiratory volume in the first second; satO2, saturated oxygen; SD, standard 
deviation; U/L, units per litre.
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are to be reserved for situations in which viruses are present 
in the community; otherwise, this diagnosis could lead to 
a significant economic cost. Rapid viral antigen detection 
with immunochromatography tests has a low diagnostic 
  sensitivity, is not very useful, and is too expensive to be used 
in nonepidemic situations.30
Conclusion
In conclusion, we stress that differentiating the etiology of 
AE-COPD on the basis of clinical and laboratory data is 
difficult in common clinical practice.
In our experience, the most profitable diagnostic tests to 
identify the possible cause of the acute decompensation of 
a patient with COPD are the conventional sputum test for 
bacteria and molecular biology techniques for viruses.
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